Pride and Pioneers

Pride and pioneers NRW's behemoth chemical companies generate about one third of the German chemical industry's global sales. For biotechnology, this dominance can be both a blessing and a curse. By Ludger Wess The production of 200 liter batches of resin used in Qiagen's spin columns for the isolation of nucleic acids. © Juergen Bindrim For more than a century, the state of North Rhine-Westphalia (NRW) has been the heartland o

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

By Ludger Wess

For more than a century, the state of North Rhine-Westphalia (NRW) has been the heartland of Germany's pharma and chemistry industry. Today, while the chemical industry is still strong, Germany is no longer the pharmacy of the world although NRW still houses a significant portion of companies active in pharmaceuticals. This amounts to about 150 companies, mostly small and medium-sized enterprises; only four have more than 1,000 employees. Most global pharmaceutical companies are represented in NRW—by subsidiaries, production facilities, or distribution centers—a reflection of the highly qualified employee base and the size of the market. For example, the German headquarters of Japanese company Takeda Pharma is located in Aachen, of Wyeth Pharma in Münster, and of Janssen-Cilag (Johnson & Johnson) in Neuss. Other companies with a presence in the state include Bayer Schering Pharma and Schwarz Pharma (UCB).

The presence of big corporations has impacted the state's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ludger Wess

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide